Dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-24. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
vacuole Any of a class of enclosed, fluid-filled compartments present in many eukaryotic cells as well as bacteria, often large and conspicuous under the microscope and serving any of a huge variety of functions, including acting as a resizable reservoir for the storage of water, metabolic waste, toxins, or foreign material; maintaining cellular homeostasis and hydrostatic pressure; supporting immune functions; housing symbiotic bacteria; and assisting in the degradation and recycling of old cellular components.
Covalent modification: Functionalization with carboxyl groups can reduce cellular and pulmonary toxicity by suppressing NLRP3 inflammasome activation and downregulating pro-inflammatory cytokines (e.g., IL-1β, TGF-β1, PDGF-AA). PEGylation, the covalent attachment of polyethylene glycol (PEG), reduces cellular uptake, protein adsorption, oxidative stress, and immune activation, reducing immune recognition and systemic inflammation.
=== 15 July === The Russian-installed governor of Sevastopol claimed that a house was damaged by falling drone debris near Cape Fiolent. The Russian defence ministry claimed that six drones were shot down over Crimea. The HUR and volunteer hackers carried out a cyberattack on websites in Russia belonging to entities involved in the war effort against Ukraine. In Russia, the governor of Lipetsk Oblast claimed that an electrical substation was struck by a drone in Stanovlyansky District, while the governor of Bryansk Oblast claimed that 15 drones were shot down over five districts. Lithuania and Vilnius Combined Heat and Power Plant gave Ukraine equipment for a thermal power plant.
The goal of wound care is to promote an environment that allows a wound to heal as quickly as possible, with emphasis on restoring both form and function of the wounded area. Although optimal treatment strategies vary greatly depending on the specific cause, size, and age of a particular wound, there are universal principles of wound management that apply to all wounds. After a thorough evaluation is performed, all wounds should be properly irrigated and debrided. Proper cleansing of a wound is critical to prevent infection and promote re-epithelialization. Further efforts should be made to eliminate/limit any contributing factors to the wound (e.g. diabetes, pressure, etc.) and optimize the wound's healing ability (i.e. optimize nutritional status). The end goal of wound management is closure of the wound which can be achieved by primary closure, delayed primary closure, or healing by secondary intention, each of which is discussed below. Pain control is a mainstay of wound management, as wound evaluation, wound cleansing, and dressing changes can be a painful process.
=== The 1978 reconstitution === Following a number of episodes, the three 1962 representative bodies were replaced by four new associations in 1978, including the AGSI. The association moved quickly to place a pay claim, and has remained very active since. Its first general secretary was the secretary of the preceding body, Derek Nally, a sergeant from County Wexford, who was succeeded in 1983 by P.J. Rogan for a year. In 2021, two members of the National Executive raised questions about the accuracy of the AGSI accounts, and they, and then two more, resigned, and the organisation's trustees raised a formal query in their annual report. Although members of the NEC are elected from branches, the resignations were described as "human resources matters" by the AGSI president, as the association's leadership promoted constitutional changes. The accounts were signed off by the AGSI's auditors, and annual delegate conference. In 2023, during disputes with the Garda authorities over rosters for front-line Gardai, the AGSI declined to join the Garda Representative Association in their action.
Sources: en.wikipedia.org
The BBC tells Gary Lineker he cannot present BBC One's Match of the Day until an agreement can be reached over his social media use. COVID-19 in the UK: Office for National Statistics data for the week ending 28 February indicates COVID-19 cases are rising in Scotland, but the picture is unclear in the rest of the UK. In England, the number of people testing positive for COVID-19 was estimated to be 1,333,400, equating to 2.38% of the population, or around 1 in 40 people. In Scotland, the figure was 128,400, equating to 2.44% of the population or around 1 in 40 people. 11 March The BBC apologises for 'limited' sports broadcasts, as a growing number of TV and radio presenters drop out of key programmes in support of Gary Lineker, amid an ongoing debate over impartiality. The Bank of England announces that the UK arm of Silicon Valley Bank is to enter insolvency, following the demise of its US parent, the largest banking collapse since the 2008 financial crisis. Many UK tech startups are prevented from accessing cash to pay staff. 12 March – The UK government announces that charges for prepayment energy meters are to be brought into line with those for customers paying by direct debit from 1 July, saving an average of £45 per year. 13 March HSBC agrees to buy the UK arm of Silicon Valley Bank, allowing UK tech firms and customers to access money and services as normal. Gary Lineker is allowed to return to presenting football, as the BBC announces an independent review of its social media guidelines.
=== Ligand removal === In many cases, as in various high-temperature catalytic applications of Au, the removal of the capping ligands produces more desirable physicochemical properties. The removal of ligands from colloidal gold while maintaining a relatively constant number of Au atoms per Au NP can be difficult due to the tendency for these bare clusters to aggregate. The removal of ligands is partially achievable by simply washing away all excess capping ligands, though this method is ineffective in removing all capping ligand. More often ligand removal achieved under high temperature or light ablation followed by washing. Alternatively, the ligands can be electrochemically etched off.
== Bibliography == Khalaf, Issa (1991). Politics in Palestine: Arab Factionalism and Social Disintegration, 1939–1948. SUNY Press. ISBN 978-0-7914-0707-3 Levenberg, Haim (1993). Military Preparations of the Arab Community in Palestine: 1945–1948. London: Routledge. ISBN 978-0-7146-3439-5 Milton-Edwards, Beverly (1999). Islamic Politics in Palestine. I. B. Tauris. p. 25. ISBN 978-0-8223-2814-8 – via Internet Archive. David Tal (2004) "Israel-Arab War, 1948 -1949/ Armistices" Routledge ISBN 978-0-7146-5275-7 Sayigh, Yezid (2000). Armed Struggle and the Search for State: The Palestinian National Movement, 1949–1993. Oxford: Oxford University Press. ISBN 978-0-19-829643-0 Segev, Tom. One Palestine, Complete: Jews and Arabs Under the British Mandate. Trans. Haim Watzman. New York: Henry Holt and Company, 2001. ISBN 978-0-316-64859-2
Selenium has bimodal biological action depending on the concentration. At low nutritional doses, selenium acts as an antioxidant through selenoproteins, scavenging ROS, supporting cell survival and growth; while, at supra-nutritional higher pharmacological doses, selenium acts as a pro-oxidant generating ROS and inducing cell death. In cancer, studies have been conducted mostly on the benefits of selenium intake in reducing the risk of cancer incidence at the nutritional level; however, fewer studies have explored the effects of supra-nutritional or pharmacological doses of selenium on cancer. "Although an inverse association between selenium exposure and the risk of some types of cancer was found in some observational studies, this cannot be taken as evidence of a causal relation, and these results should be interpreted with caution... Conflicting results including inverse, null and direct associations have been reported for some cancer types... RCTs assessing the effects of selenium supplementation on cancer risk have yielded inconsistent results... To date, no convincing evidence suggests that selenium supplements can prevent cancer in humans."
=== Gastrointestinal distress === Nausea, vomiting, anorexia, diarrhea, abdominal cramps, and constipation are common side-effects of chemotherapeutic medications that kill fast-dividing cells. Malnutrition and dehydration can result when the recipient does not eat or drink enough, or when the person vomits frequently, because of gastrointestinal damage. This can result in rapid weight loss, or occasionally in weight gain, if the person eats too much in an effort to allay nausea or heartburn. Weight gain can also be caused by some steroid medications. These side-effects can frequently be reduced or eliminated with antiemetic drugs. Low-certainty evidence also suggests that probiotics may have a preventative and treatment effect of diarrhoea related to chemotherapy alone and with radiotherapy. However, a high index of suspicion is appropriate, since diarrhoea and bloating are also symptoms of typhlitis, a very serious and potentially life-threatening medical emergency that requires immediate treatment.
Sources: en.wikipedia.org
Research has shown that a mutation of G—>C in the −6 position of the β-globin gene (β+45; human) disrupted the haematological and biosynthetic phenotype function. This was the first mutation found in the Kozak sequence and showed a 30% decrease in translational efficiency. It was found in a family from the Southeast Italy and they suffered from thalassaemia intermedia. Similar observations were made regarding mutations in the position −5 from the start codon, AUG. Cytosine in this position, as opposed to thymine, showed more efficient translation and increased expression of the platelet adhesion receptor, glycoprotein Ibα in humans. Mutations to the Kozak sequence can also have drastic effects upon human health; in particular, certain forms of congenital heart disease are caused by Kozak sequence mutations in the GATA4 gene's 5' untranslated region. The GATA4 gene is responsible for gene expression in a wide variety of tissues including the heart. When the guanosine at the -6 position in the Kozak sequence of GATA4 is mutated to a cytosine, a reduction in GATA4 protein levels results, which leads to a decrease in the expression of genes regulated by the GATA4 transcription factor and linked to the development of atrial septal defect. The ability of the Kozak sequence to optimize translation can result in novel initiation codons in the typically untranslated region of the 5′ (5′ UTR) end of the mRNA transcript. A G to A mutation was described by Bohlen et al.
== Mechanism of action == Naltrexone and its active metabolite, 6-β-naltrexol, are competitive antagonists at μ-opioid, κ-opioid, and, to a lesser extent, δ-opioid receptors. Standard therapeutic doses of naltrexone block these receptors, achieving two main effects: first, they prevent the inhibition of GABA receptors, which normally suppress neuron activity; many recreational drugs inhibit GABA, thereby increasing neuronal activation, and by blocking GABA inhibition, normal GABA activity resumes. Second, naltrexone blocks dopamine release, since many recreational drugs stimulate dopamine as part of the brain's reward system, which generates feelings of pleasure. As naltrexone is a competitive antagonist at the identical sites of action of many opioid agonists, such as morphine, care must be taken to ensure that low-dose naltrexone is not taken near the same time as these medications, as they will not be as efficacious in relieving pain.
=== Plaque psoriasis === Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.
=== NASA Visualization Explorer === On July 26, 2011, NASA released the NASA Visualization Explorer app for the iPad. The application delivers real-time satellite data, including movies and stills, of Earth, that enable users to learn about subjects such as climate change, Earth's dynamic systems and plant life on land and in the oceans. The content is accompanied by short descriptions about the data and why it is important.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.